Previous 10 | Next 10 |
PRINCETON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock (or pre-funded warrants in li...
2023-05-17 10:03:19 ET Gainers: XBiotech ( XBIT ) +32% . Impel Pharmaceuticals ( IMPL ) +30% . Immutep ( IMMP ) +14% . Corvus Pharmaceuticals ( CRVS ) +13% . Sientra ( SIEN ) +10% . Losers: Intercept Pharmaceuticals ( ICP...
2023-05-12 19:09:10 ET Agile Therapeutics, Inc. (AGRX) Q1 2023 Earnings Conference Call May 11, 2023 04:30 PM ET Company Participants Matt Riley - Head, Investor Relations Al Altomari - Chairman & Chief Executive Officer Conference Call Participants O...
2023-05-11 16:07:44 ET Agile Therapeutics press release ( NASDAQ: AGRX ): Q1 GAAP EPS of -$5.91 beats by $1.59 . Revenue of $3.81M (+116.5% Y/Y) beats by $0.41M . For further details see: Agile Therapeutics GAAP EPS of -$5.91 beats by $1.59, revenue of $3...
Twirla Delivers Single-Quarter Records for Retail and Non-Retail Demand; Both Channels Up 20% in First Quarter 2023 vs Fourth Quarter 2022 Total OPEX down 8% in First Quarter 2023 vs Fourth Quarter 2022 Company Reaffirms Expected Full Year 2023 Net Revenue in Range of $25-$30 Mi...
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the market close on Thursday, May 11, 2023. Following the release, the Company will host a l...
PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla ® demand, net revenue and operating expenses. Expected First Quarter 2023 Performance ...
2023-04-26 09:06:41 ET Agile Therapeutics ( NASDAQ: AGRX ) has received a notification letter from the Nasdaq, informing the Co. that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule. On April 25, 2023, Nasdaq provided conf...
PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it has received a notification letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq...
2023-04-11 13:16:16 ET Gainers: Innovative Eyewear ( LUCY ) +157% . WW International ( WW ) +50% . Brenmiller Energy ( BNRG ) +45% . Brookdale Senior Living ( BKD ) +34% . ZeroFox Holdings ( ZFOX ) +31% . Kura Sushi USA ( K...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
NASDAQ Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...